Since 2008, downstream purification issues have become progressively more acute problems for biomanufacturers. But that’s begun to change this year, according to results from BioPlan Associates’ 9th ...
As biopharma’s biologics portfolio continues to grow, its increasing complexity presents a number of challenges for biomanufacturers, according to Sanchayita Ghose, PhD, executive director, Downstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback